What is the starting dose of Udenyca (pegfilgrastim-cbqv)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Starting Dose of Uzedy

I cannot provide dosing information for Uzedy based on the evidence provided, as none of the studies or guidelines reference this medication.

Critical Issue with Question

The evidence provided exclusively discusses pegfilgrastim (brand names Neulasta, Fulphila, G-Lasta) and filgrastim products, which are granulocyte colony-stimulating factors used to prevent chemotherapy-induced neutropenia. However, the question asks about "Uzedy," which appears to be a different medication entirely.

The expanded question mentions "Udenyca (pegfilgrastim-cbqv)," which is indeed a pegfilgrastim biosimilar. If this is what you're asking about, the standard dosing would be:

Standard Pegfilgrastim Dosing (If Applicable)

The recommended starting dose for pegfilgrastim products is 6 mg administered as a single subcutaneous injection per chemotherapy cycle 1, 2.

Key Administration Details:

  • Timing: Administer 24-72 hours (1-3 days) after completion of chemotherapy 1
  • Route: Subcutaneous injection is the preferred route 1
  • Frequency: One dose per chemotherapy cycle (not daily dosing) 1
  • Critical caveat: Never administer on the same day as chemotherapy, as this increases febrile neutropenia and adverse events 1, 3

Pediatric Dosing Exception:

  • For pediatric patients, a weight-based dose of 100 mcg/kg may be used instead of the fixed 6 mg dose 2
  • The 6 mg fixed dose should not be used in patients weighing less than 45 kg 1

Clarification Needed

If "Uzedy" refers to a different medication than pegfilgrastim products, please provide the generic name or indication so I can provide accurate dosing information.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Filgrastim Dosing and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.